Cibeles Pharmaceuticals Private Limited is a proud partner of BDR pharmaceuticals.
BDR has achieved the distinction of winning the API company of the year award and Excellence in Research based on data and analytics.
BDR is at the forefront of synthesising drugs and manufacturing several first-time in India drugs in oncology, critical care, COVID care and other therapies.
Over the last 15 years, the BDR group of companies has grown steadily and has become a trusted name in the pharmaceutical industry in both domestic and international arenas.
BDR Group focuses on development in 4 specialised therapeutic segments, viz., oncology, critical care, gynaecology, and neurology.
Over the years, BDR has built a formidable reputation for its specialisation in the early identification, development, and introduction of new molecules, in a continuous endeavour to make globally available high-cost medicines to the local masses at affordable prices.
BDR is the proud recipient of the “Golden Award for Best Exporter” from Pharmexcil (Export Promotion Council) since 2010.
Only recently, BDR has received EUGMP Approval for it’s Baroda plant & is planning aggressively on entering into regulatory markets.
BDR MISSION
“To become strategic innovator & enhance healthcare by endowing the society with innovative products & medicines at affordable prices in life saving category.”
BDR VISION
“Early identification of newer molecules for life-threatening disease that encourage us to advance development & introduction of products through the strength of backward integration of developing & manufacturing APIs to facilitate humankind.”
The company has now garnered investor interest. Recently, BDR received funding of Rs 685 crore from Multiples Private Equity by diluting 9.3 percent of the equity at a valuation of Rs 7,365 crore.
BDR Pharma plans to use the fresh funds to build a facility in the US, start manufacturing some complex molecules and get into biosimilars (an identical copy of the original product manufactured by a different company), a move which is expected to put it in the same league as Indian pharma giants such as Biocon, Cipla, Dr Reddy’s and more.
Click here to visit BDR website
Cibeles Pharmaceuticals Private Limited is a proud partner of BDR pharmaceuticals.
BDR has achieved the distinction of winning the API company of the year award and Excellence in Research based on data and analytics.
BDR is at the forefront of synthesising drugs and manufacturing several first-time in India drugs in oncology, critical care, COVID care and other therapies.
Over the last 15 years, the BDR group of companies has grown steadily and has become a trusted name in the pharmaceutical industry in both domestic and international arenas.
BDR Group focuses on development in 4 specialised therapeutic segments, viz., oncology, critical care, gynaecology, and neurology.
Over the years, BDR has built a formidable reputation for its specialisation in the early identification, development, and introduction of new molecules, in a continuous endeavour to make globally available high-cost medicines to the local masses at affordable prices.
BDR is the proud recipient of the “Golden Award for Best Exporter” from
Pharmexcil (Export Promotion Council) since 2010.
Only recently, BDR has received EUGMP Approval for it’s Baroda plant & is planning aggressively on entering into regulatory markets.
BDR MISSION
“To become strategic innovator & enhance healthcare by endowing the society with innovative products & medicines at affordable prices in life saving category.”
BDR VISION
“Early identification of newer molecules for life-threatening disease that encourage us to advance development & introduction of products through the strength of backward integration of developing & manufacturing APIs to facilitate humankind.”
The company has now garnered investor interest. Recently, BDR received funding of Rs 685 crore from Multiples Private Equity by diluting 9.3 percent of the equity at a valuation of Rs 7,365 crore.
BDR Pharma plans to use the fresh funds to build a facility in the US, start manufacturing some complex molecules and get into biosimilars (an identical copy of the original product manufactured by a different company), a move which is expected to put it in the same league as Indian pharma giants such as Biocon, Cipla, Dr Reddy’s and more.
Click here to visit BDR website